Global Blood Therapeutics, Inc. (GBT) stock rallied over 4.32% intraday to trade at $66.6 a share on NASDAQ. The stock opened with a gain of 40.48% at $66.69 and touched an intraday high of $66.77, rising 4.32% against the last close of $63.84. The stock went to a low of $66.545 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue210.87 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
Global Blood Therapeutics, Inc. (NASDAQ: GBT) stock price is $66.6 as of the last check on Monday, August 8. During the trading session, GBT stock reached the peak price of $66.77 while $66.545 was the lowest point it dropped to.
The NASDAQ listed GBT is part of Biotechnology industry that operates in the broader Health Care sector. Global Blood Therapeutics, Inc. , a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
Ms. Nazila Habibizad
Sr. VP of Operations
Dr. Ted W. Love M.D.
Pres, CEO & Director
Mr. Jeffrey S. Farrow
CFO & Principal Accounting Officer
Ms. Patricia Borga Suvari
Chief Legal Officer & Sec.
GBT stock traded closed the last session at $66.615, which is $2.759999999999991 or 4.32% lower than its previous close of $63.84. GBT's current trading price is 207.62% lower than its 52-week high of $73.02 where as its distance from 52-week low of 21.65% is -8.79%.
Number of GBT employees currently stands at -. GBT operates from 181 Oyster Point Boulevard, South San Francisco, CA 94080, United States.
Official Webiste of $GBT is: https://www.gbt.com
GBT stock volume for the day was 39,300,793 shares while in the previous session number of GBT shares traded was 34,026,350 . The average number of GBT shares traded daily for last 3 months was 1.82 Million.
The percentage change in GBT stock occurred in the recent session was 4.32% while the dollar amount for the price change in GBT stock was $2.759999999999991.
In the recent session, the day high for GBT stock was $66.77 while the low for GBT stock touched on the day was $66.545.
The market value of GBT currently stands at 3.26 Billion with its latest stock price at $66.6 and 64.84 Million of its shares outstanding.